Publications by authors named "Judith A Fox"

Claim this Profile
I
Immunodepletion of MDSC by AMV564, a novel bivalent, bispecific CD33/CD3 T cell engager, ex vivo in MDS and melanoma.
Pingyan Cheng, Xianghong Chen, Robert Dalton, Alexandra Calescibetta, Tina So, Judith A Fox

Mol Ther· June 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase Ib dose-escalation study of the selective, non-covalent, reversible Bruton's tyrosine kinase inhibitor vecabrutinib in B-cell malignancies.
John N Allan, Javier Pinilla-Ibarz, Douglas E Gladstone, Krish Patel, Jeff P Sharman, Judith A Fox

Haematologica· April 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evaluation of vecabrutinib as a model for noncovalent BTK/ITK inhibition for treatment of chronic lymphocytic leukemia.
Billy Michael Chelliah Jebaraj, Annika Müller, Rashmi Priyadharshini Dheenadayalan, Sascha Endres, Philipp M Roessner, Judith A Fox

Blood· February 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Vecabrutinib inhibits B-cell receptor signal transduction in chronic lymphocytic leukemia cell types with wild-type or mutant Bruton tyrosine kinase.
Burcu Aslan, Stefan Edward Hubner, Judith A Fox, Pietro Taverna, William G Wierda

Haematologica· January 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase 3 results for vosaroxin/cytarabine in the subset of patients ≥60 years old with refractory/early relapsed acute myeloid leukemia.
Farhad Ravandi, Ellen K Ritchie, Hamid Sayar, Jeffrey E Lancet, Michael D Craig, Judith A Fox

Haematologica· November 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Enhancement of radiosensitivity by the novel anticancer quinolone derivative vosaroxin in preclinical glioblastoma models.
Giovanni Luca Gravina, Andrea Mancini, Claudia Mattei, Flora Vitale, Francesco Marampon, Judith A Fox

Oncotarget· May 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Characterization of CD33/CD3 Tetravalent Bispecific Tandem Diabodies (TandAbs) for the Treatment of Acute Myeloid Leukemia.
Uwe Reusch, Kimberly H Harrington, Chelsea J Gudgeon, Ivica Fucek, Kristina Ellwanger, Judith A Fox

Clin Cancer Res· December 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Molecular and Pharmacologic Properties of the Anticancer Quinolone Derivative Vosaroxin: A New Therapeutic Agent for Acute Myeloid Leukemia.
Gene C Jamieson, Judith A Fox, Ming Poi, Stephen A Strickland

Drugs· September 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Vosaroxin plus cytarabine versus placebo plus cytarabine in patients with first relapsed or refractory acute myeloid leukaemia (VALOR): a randomised, controlled, double-blind, multinational, phase 3 study.
Farhad Ravandi, Ellen K Ritchie, Hamid Sayar, Jeffrey E Lancet, Michael D Craig, Judith A Fox

Lancet Oncol· September 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
REVEAL-1, a phase 2 dose regimen optimization study of vosaroxin in older poor-risk patients with previously untreated acute myeloid leukaemia.
Robert K Stuart, Larry D Cripe, Michael B Maris, Maureen A Cooper, Richard M Stone, Judith A Fox

Br J Haematol· March 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase 1b/2 study of vosaroxin in combination with cytarabine in patients with relapsed or refractory acute myeloid leukemia.
Jeffrey E Lancet, Gail J Roboz, Larry D Cripe, Glenn C Michelson, Judith A Fox

Haematologica· February 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Iron(III)-binding of the anticancer agents doxorubicin and vosaroxin.
Katja Dralle Mjos, Jacqueline F Cawthray, Gene Jamieson, Judith A Fox, Chris Orvig

Dalton Trans· February 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Homologous recombination repair is essential for repair of vosaroxin-induced DNA double-strand breaks.
Rachael Elizabeth Hawtin, David Elliot Stockett, Oi Kwan Wong, Cecilia Lundin, Thomas Helleday, Judith Ann Fox

Oncotarget· November 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Voreloxin, a first-in-class anticancer quinolone derivative, acts synergistically with cytarabine in vitro and induces bone marrow aplasia in vivo.
Caroline D Scatena, Jeffrey L Kumer, Jennifer P Arbitrario, Anthony R Howlett, Rachael E Hawtin, Judith A Fox

Cancer Chemother Pharmacol· October 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase I and pharmacologic study of SNS-032, a potent and selective Cdk2, 7, and 9 inhibitor, in patients with advanced chronic lymphocytic leukemia and multiple myeloma.
Wei-Gang Tong, Rong Chen, William Plunkett, David Siegel, Rajni Sinha, Judith A Fox

J Clin Oncol· June 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Voreloxin, a first-in-class anticancer quinolone derivative, in relapsed/refractory solid tumors: a report on two dosing schedules.
Ranjana H Advani, Herbert I Hurwitz, Michael S Gordon, Scot W Ebbinghaus, David S Mendelson, Judith A Fox

Clin Cancer Res· April 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Voreloxin is an anticancer quinolone derivative that intercalates DNA and poisons topoisomerase II.
Rachael E Hawtin, David E Stockett, Jo Ann W Byl, Robert S McDowell, Tan Nguyen, Judith A Fox

PLoS One· April 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
SNS-032 is a potent and selective CDK 2, 7 and 9 inhibitor that drives target modulation in patient samples.
Andrew Conroy, David E Stockett, Duncan Walker, Michelle R Arkin, Ute Hoch, Judith A Fox

Cancer Chemother Pharmacol· September 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Mechanism of action of SNS-032, a novel cyclin-dependent kinase inhibitor, in chronic lymphocytic leukemia.
Rong Chen, William G Wierda, Sherri Chubb, Rachael E Hawtin, Judith A Fox

Blood· May 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase I pharmacokinetic and pharmacodynamic study of TKI258, an oral, multitargeted receptor tyrosine kinase inhibitor in patients with advanced solid tumors.
Debashis Sarker, Rhoda Molife, T R Jeffrey Evans, Maryon Hardie, Cheryl Marriott, Judith A Fox

Clin Cancer Res· April 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Characterization of a CC49-based single-chain fragment-beta-lactamase fusion protein for antibody-directed enzyme prodrug therapy (ADEPT).
Ralph F Alderson, Brian E Toki, Martin Roberge, Wei Geng, Joshua Basler, Judith A Fox

Bioconjug Chem· July 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Tissue distribution and receptor-mediated clearance of anti-CD11a antibody in mice.
Greg P Coffey, Judith A Fox, Susanne Pippig, Susan Palmieri, Barbara Reitz

Drug Metab Dispos· May 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Characterization of humanized antibodies secreted by Aspergillus niger.
Michael Ward, Cherry Lin, Doreen C Victoria, Bryan P Fox, Judith A Fox

Appl Environ Microbiol· May 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetics of rhuMAb CD18, a recombinant humanised monoclonal antibody fragment to CD18, in normal healthy human volunteers.
David E Allison, Steven G Gourlay, Eugene Koren, Robert M Miller, Judith A Fox

BioDrugs· August 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Enhanced tumor killing by Apo2L/TRAIL and CPT-11 co-treatment is associated with p21 cleavage and differential regulation of Apo2L/TRAIL ligand and its receptors.
Hong Xiang, Judith A Fox, Klara Totpal, Mina Aikawa, Kelly Dupree

Oncogene· May 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis